Month: August 2025

Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the United States Food and Drug Administration (FDA) has granted RMAT designation to GLPG5101, a second generation anti-CD19/4-1BB CAR-T product candidate for the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL).  The RMAT designation was established under the U.S. 21st Century Cures Act to accelerate development and review of promising cell and gene therapies for serious or life-threatening conditions. To qualify for RMAT designation, GLPG5101 demonstrated preliminary clinical evidence suggesting it has the potential to treat, modify, reverse, or cure a serious or life-threatening disease. Clinical data derived from the ongoing ATALANTA-1 study with GLPG5101 in patients...

Nasdaq CopenhagenEuronext DublinLondon Stock ExchangeOther stakeholders 6 August 2025Ringkjøbing Landbobank’s quarterly report for the first half of 2025 The bank’s board of directors and general management today approved the report for the first half of 2025. The bank delivers core earnings of DKK 1,580 million and net profit of DKK 1,191 million in the first half of the year. The net profit is equivalent to a 21% p.a. return on equity. Core earnings(DKK million) H1 2025 H1 2024 2024 2023 2022 2021Total core income 2,090 2,051 4,068 3,828 2,862 2,433Total expenses and depreciation 534 508 1,044 963 891 817Core earnings before impairment charges for loans 1,556 1,543 3,024 2,865 1,971 1,616Impairment charges for loans etc. +24 +1 +3 -1 -2 -68Core earnings 1,580 1,544 3,027 2,864 1,969 1,548Result for the portfolio...

Sampo plc, half-year financial report, 6 August 2025 at 8:30 am EEST Sampo Group’s results for January–June 2025Like-for-like top-line growth of 8 per cent, supported by continued strong momentum in the private businesses in the Nordics and in the UK. Favourable claims environment throughout the first half and positive underlying trend in the Nordics supported underwriting margins, leading to an improved combined ratio of 83.6 per cent. The underwriting result increased by 25 per cent on a currency adjusted basis to EUR 729 million on the back of strong growth and margin improvement. Operating EPS strengthened by 13 per cent to EUR 0.25, driven by the strong underwriting performance offsetting lower investment returns and an increase in the share count. Following the strong second quarter performance, the outlook for 2025 underwriting...

Nasdaq CopenhagenEuronext DublinLondon Stock Exchange        Other stakeholders                 Date: 6 August 2025 Upward adjustment of expectations for 2025 Ringkjøbing Landbobank is upwardly adjusting its expectations for net profit for 2025. The expectations for net profit for the year are upwardly adjusted from the DKK 1,800 – 2,200 million range to the DKK 2,000 – 2,350 million range. The upward adjustment is based on a continued good credit quality and a loss and impairment level that has developed better than originally budgeted for 2025. In addition, the bank’s total income for the full year is now expected to be at the same level as the total income in 2024. The expectations for net profit for 2025 are subject to uncertainty and depend on developments in the financial markets and macroeconomic conditions. Yours sincerely Ringkjøbing...

6 August 2025, Antwerp, Belgium: VGP NV (‘VGP’ or ‘the Group’), a European provider of high-quality logistics and semi-industrial real estate, announces the details for the webcast to review its financial results for the first half year ending 30 June 2025: Thursday, 21 August 2025 at 10.30 a.m. (CET) Webcast link:https://vgp.engagestream.companywebcast.com/1h2025-results The link above will allow you to register for the event. The presentation can be attended from your laptop, tablet or mobile device. The video will stream through your selected device.Please join the webcast 5-10 minutes prior to the start time. The financial results are scheduled to be released at approximately 7:00 a.m. (CET) on the date noted above, and presentation slides will be made available on www.vgpparks.eu/en/investors/publications/ under Financial...

Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. (“Vigil”). This acquisition strengthens Sanofi’s early-stage pipeline in neurology with VG-3927, a novel, oral, small-molecule TREM2 agonist, which will be evaluated in a phase 2 clinical study in patients with Alzheimer’s disease. In addition, the acquisition of Vigil’s preclinical pipeline will further strengthen Sanofi’s research in various neurodegenerative diseases. In June 2024, Sanofi made a $40 million strategic investment in Vigil that included the exclusive right of first negotiation for an exclusive license, grant, or transfer of rights to research, develop, manufacture, and commercialize VG-3927. Under the terms of the acquisition agreement, Sanofi and Vigil have...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL  Reference is made to the stock exchange announcement made by Prosafe SE (“Prosafe” or the “Company“) on 23 July 2025 regarding commencement of the subscription period (the “Subscription Period“) for an offering of up to 17,868,651 warrants (the “Warrants“) (the “Warrants Offering“). The Subscription Period will end today, 6 August 2025, at 16:30 (CEST). To subscribe for Warrants, a properly completed subscription form must be submitted to the Receiving Agent...

Ad hoc announcement pursuant to Art. 53 LRBaar, Switzerland, August 6, 2025 First half of 2025 at a glance:Net revenue of CHF 140.0 million (H1/2024: CHF 142.1 million), reflecting a slight increase of 0.2% at constant currencies and a decrease of 1.5% at actual currencies. Incoming orders amounted to CHF 156.6 million (H1/2024: CHF 166.1 million), reflecting a decrease of 4.2% at constant currencies and a decrease of 5.7% at actual currencies. EBITDA increased by CHF 1.6 million to CHF 12.1 million (H1/2024: CHF 10.5 million), and the EBITDA margin increased by 1.2 percentage points to 8.6% (H1/2024: 7.4%). Group profit amounted to CHF 2.2 million (H1/2024: CHF 2.9 million), impacted by predominantly unrealized foreign currency exchange effects. Net cash position amounted to CHF 29.5 million (H1/2024: CHF 16.5 million), with a solid...